Article
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
Journal of medicinal chemistry - 28 Mar 2024
Wang Zi-Xuan, Li Qing-Qing, Cai Jiao, Wu Jia-Zhen, Wang Jing-Jing, Zhang Meng-Yuan, Wang Qing-Xin, Tong Zhen-Jiang, Yang Jin, Wei Tian-Hua, Zhou Yun, Dai Wei-Chen, Ding Ning, Leng Xue-Jiao, Sun Shan-Liang, Xue Xin, Yu Yan-Cheng, Yang Ye, Li Nian-Guang, Shi Zhi-Hao
Abstract excerpt
Over the past decades, the role of rearranged during transfection (RET) alterations in tumorigenesis has been firmly established. RET kinase inhibition is an essential therapeutic target in patients with RET-altered cancers. In clinical practice, initial efficacy can be achieved in patients through the utilization of multikinase inhibitors (MKIs) with RET inhibitory activity. However, the effectiveness of these...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.